Introduction
is poor 3 and patients resist re-introduction of drugs for treatment. This makes them willing converts to phytomedicine and nutraceuticals in the erroneous belief that as 'natural products', they are like food and devoid of untoward effects. Encountering a few among local patients in this sub-Sahara African facility, against the back drop that it has not been reported in Blacks despite their association with resistant hypertension, 5 one was encouraged to scrutinize the hypertension database of this specialized hypertension service. This was with a view to assessing the quantum of the problem, and to be able to plan containment strategies. No series of this entity has been reported in our sub-region to the best of the author's knowledge.
Methodology
The author runs a purely outpatient-based specialized hypertension service in Jos, Nigeria where patients come on their own volition or are referred from about 10 out of the 36 states of Nigeria. Occasionally they come from far-flung states on the advice of their relations resident in Jos. The reasons for referral vary but are mostly for hypertension associated with target organ involvement, co-morbidities and difficulties to control. Effectively, patients come from all cultural backgrounds and cut across sex and socioeconomic strata in Nigeria, the most populous Black nation in the world.
Patients are seen solely by the author and are given appointments ranging from 2-12 weeks. Over 3 months (May-July 2016) to cover a 12-week cycle which ensured all attendees were captured, all patients with hypertension consulting the author had their records evaluated for intolerance to three or more different classes of anti-hypertensives. This was made easy because as a matter of practice, any reported drug intolerance is usually documented on the case note to avoid patients being prescribed such drugs subsequently. Drugs prescribed depended on patients' cardiovascular disease profile. The consent for use of data of those with documented evidence of intolerance to three or more anti-hypertensives was sought and given in all instances. Their ages, sex, control status and co-morbidities were extracted from the records and entered on a data collection sheet. No patient was recorded more than once. Data were anonymized to avoid breach of confidentiality, obviating the need for Institutional Board Review. Only frequencies and percentages are presented.
Results
A total of 489 patients with hypertension were seen, 271 (55.4%) of whom were women. About half 248/489 were uncontrolled. Overall, 15 out of the 489 (3.1%) consisting of 10 women and five men, satisfied the definition of MDI. Their ages ranged from 38-71 years of age with most of them being in their 7th decade of life. All the 5 men in this sub-group were uncontrolled while 7 out of the 10 women were uncontrolled. Overall, two of the women suffered from premenstrual syndrome. A total of 8 out of the 15 (2 men, 6 women) had a history suggestive of allergy; and two (1 man, 1 woman) were on treatment for anxio-depressive illness. Most drug classes were represented and patients reported palpitations, dizziness, tinnitus, insomnia, headache, body aches and being restless as symptoms of intolerance, which were of such severity to interfere with daily routine and prompt discontinuation before reporting to author. In some cases, the intolerance was reported with one brand only of a drug and not the others, or they would initially tolerate a drug but show intolerance later and vice versa. Table 1 shows details of drugs the patients were intolerant of with co-morbidities and current regimen.
Discussion
There are individual and group variations in drug response in different disease entities. 6 With hypertension, inter-patient variability in drug response could be huge, and reasons for varying response to a particular drug and cardiovascular outcomes are still blurred. 7 As a result, a more person-centered approach to treatment of hypertension would be beneficial. This nonuniformity in response led some workers to wade into a new frontier of 'personalized medicine', which for hypertension, seeks to avert patient-specific risk factors for ADRs. 8 Though most ADRs to antihypertensives do not threaten life directly, they do so indirectly by contributing to nonadherence and adverse outcomes with heavy economic burden. 9 Generally, ADRs are said to be a great burden to patients and health systems alike, with the majority being predictable (Type A/on-target) and about 20% which are not readily anticipated (Type B/off-target). 4 Almost all drug classes were involved and prominent symptoms of intolerance prompting discontinuation included palpitations, dizziness, tinnitus, insomnia and body aches among others. More women were affected in this series. Sex representation has varied in different series, though on balance more women are reportedly affected. 3 Physiological differences impacting on pharmacokinetics and pharmacodynamics across sexes are considered plausible. 10 Patients with a background of allergy are also said to be prone, as some of them would also have ADRs to other drug classes. 11 Overall, 8 eight of them also reacted to either or both of antibiotics or nonsteroidal anti-inflammatory drugs. (See Table  1 ). For these, altered mast cell degranulation may be the underlying mechanism. 12 An imbalance of the immune system manifesting excess activation of effector T-cells and inadequately low function of T-Reg cells has been reported in some cases. 13 In this series 8/15 gave histories suggesting allergy disease and may actually have what is called 'multiple drug allergy syndrome'. The link with anxio-depressive illness has also been made. 14 This is because of their predisposition to nocebo effect 15 and some nonpharmacologically expected as well as nonidiopathic ADRs which are exaggerated in severity. 16 Overall, 2 of the 15 patients meeting the criteria for diagnosis of MDI in this series were already on treatment for anxio-depressive disorders.
The 3.1% prevalence of MDI in this series is slightly higher than the 2.1% in the United States (US) population. 17 It is understandable since this series focused on patients with hypertension in a specialized hypertension clinic while the US data were population-wide. Some MDI reactions may arise from nonspecific histamine release. Histamine in the human circulation evokes the release of adrenaline from the adrenal glands. This would increase the rate and force of cardiac contraction 11 resulting in instances of palpitation, headache, tinnitus, increased alertness and insomnia, anxiety and panic attacks. Reactions to drug classes in one formulation as opposed to another may be due to difference in excipients used by different manufacturers or differences in physicochemical properties of solid dose formulations. 3 All considered, the fact that 12/15 patients satisfying the diagnosis of MDI had their blood pressures uncontrolled shows how much this can cause sub-optimal control and should worry clinicians caring for patients with hypertension. For these patients, it may be helpful to consider reducing total cardiovascular disease risk profile rather than pushing blood pressure reduction to an arbitrary cutoff point with attendant risk of drug reaction and its consequences. In such cases, a higher blood pressure level may be accepted as 'satisfactory goal' provided other cardiovascular disease risk factors which increase morbidity are well controlled.
In conclusion, MDI does occur in Nigerian patients with hypertension. When blood pressure control is poor and drug adherence is suspect, the possibility of MDI should be explored among other issues. Such patients should be offered staggered doses of solid formulations, liquefied or topical formulations before considering devicebased therapy. Staggered doses of solid formulations seem to work here in preventing ADRs (See Table 1 ) where drugs are given on alternate days, every third day and once a week. Liquefied and topical formulations were not readily available and hence not administered.
